Sugemalimab Plus Chemo Significantly Improves Survival in Frontline Stage IV NSCLC

The addition of the PD-L1 inhibitor sugemalimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in the frontline treatment of patients with stage IV non–small cell lung cancer. The addition of the PD-L1 inhibitor sugemalimab to chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone...